ReviewNature reviews. Cardiology2025
Clonal haematopoiesis in cardiovascular disease: prognostic role and novel therapeutic target.
Review in Nature reviews. Cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinical impact of clonal hematopoiesis on patients with solid tumors: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Colchicine and Longitudinal Dynamics of Clonal Hematopoiesis: An Exploratory Substudy of the LoDoCo2 Trial.Journal of the American College of Cardiology · 2025Trial
- Exacerbation of inflammatory bone loss in TET2-driven clonal hematopoiesis.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Review
- Atherosclerotic Cardiovascular Disease and Cancer.Immunological reviews · 2026Review
- Immunothrombotic Cell-Cell Communication Networks in Coronary Atherosclerosis: Critical Insights from Single-Cell and Spatial Systems Biology.International journal of molecular sciences · 2026Review
- Inflammatory Signatures in MDS: The Missing Link Between Genetics, Microenvironment, and Therapy.Cells · 2026Review
- Charting single-cell lineages with synthetic and natural barcodes.Nature reviews. Genetics · 2026Review
- Inflammageing and clonal haematopoiesis interplay and their impact on human disease.Nature reviews. Molecular cell biology · 2026Review
- Expanding clones, expanding aneurysms through macrophage-to-osteoclast differentiation.The Journal of clinical investigation · 2026Article
- Association BetweenGenes · 2026Review
- Add-Ons of Heart Disease from the Cardiosurgical Perspective: Gender, Blood Groups and Renal Function.Medical sciences (Basel, Switzerland) · 2026Article
- Routine inflammatory indices modify clonal hematopoiesis-related prognostic risk in patients undergoing percutaneous coronary intervention: a real-world cohort study.BMC medicine · 2026Article
- Clonal Hematopoiesis and Incident Heart Failure.JAMA cardiology · 2026Article
- Clonal Hematopoiesis of Indeterminate Potential in Cardiovascular Disease: Gene-Specific Mechanisms and Therapeutic Implications.International journal of general medicine · 2026Review
- Immuno-inflammatory-metabolic interactions in cardiovascular diseases: a review from basic mechanisms to clinical translation.Frontiers in immunology · 2026Review
- Clonal Hematopoiesis of Indeterminate Potential and Cardiometabolic Disease: Challenges, Controversies and Future Perspectives.International journal of molecular sciences · 2025Review
- How to Read a Next-Generation Sequencing Report for AML and MDS? What Hematologists Need to Know.Journal of clinical medicine · 2025Review
- Clonal Hematopoiesis and Risk of New-Onset Myocarditis and Pericarditis.JAMA cardiology · 2025Observational
- Clonal Hematopoiesis and Cardiovascular Outcomes in Older Women.Journal of the American College of Cardiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Clonal haematopoiesis is the clonal expansion of blood stem cells with acquired mutations. Clonal haematopoiesis of indeterminate potential (CHIP), traditionally defined as clonal haematopoiesis driven by a pre-leukaemic mutation in at least 2% of sequenced alleles, affects 10-20% of individuals aged >70 years. Although CHIP is considered a precursor condition for haematological malignancies, population-based data suggest that the majority of CHIP-associated mortality is attributable to non-malignant conditions, such as cardiovascular disease. Observational human studies have shown that CHIP is a strong and independent predictor of the onset and progression of atherosclerotic cardiovascular disease, heart failure and arrhythmia. In addition, findings from animal experiments suggest that CHIP is causally involved in these diseases and might be a risk factor that can be targeted with therapeutics. As our understanding of the cardiovascular implications of CHIP and other types of clonal haematopoiesis rapidly expands, it has become increasingly clear that clonal haematopoiesis subtypes have substantial heterogeneity with respect to magnitude of effect and underlying mechanisms for different cardiovascular diseases. In this Review, we discuss clonal haematopoiesis as a prognostic factor for numerous cardiovascular diseases, highlight its potential as a therapeutic target and propose a potential role for CHIP in cardiovascular precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.